Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862175 | 0.88 | P2RX7 (0.35) | P2RX7SCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4858003 | 0.86 | P2RX7 (0.36) | P2RX7SCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4864958 | 0.85 | DPP8 (0.34) | P2RX7CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL4857762 | 0.80 | ALDH1A1 (0.35) | SCN9AKMT2A | |
| SCHEMBL4863587 | 0.75 | ALDH1A1 (0.32) | SCN9AKMT2A | |
| SCHEMBL4863041 | 0.74 | POLB (0.35) | P2RX7CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL4864608 | 0.74 | P2RX7 (0.35) | P2RX7SCN9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16708438 | 0.73 | ALDH1A1 (0.39) | POLBKMT2A | |
| SCHEMBL4866160 | 0.73 | DPP8 (0.33) | P2RX7CYP1A2CYP2C9CYP2C19POLB | |
| SCHEMBL822920 | 0.73 | ALDH1A1 (0.46) | POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456311-B2 | Adamantane derivative, process for producing the same, and photosensitive material for photoresist | IDEMITSU KOSAN CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080009647-A1 | Adamantane Derivative, Process for Producing the Same, and Photosensitive Material for Photoresist | IDEMITSU KOSAN CO., LTD. (JP) | 2008-01-10 | — | — | US | disclosed |
| EP-1803708-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND PHOTOSENSITIVE MATERIAL FOR PHOTORESIST | IDEMITSU KOSAN CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009647-A1 | Adamantane Derivative, Process for Producing the Same, and Photosensitive Material for Photoresist | LSS, C1S, DHPS | P2RX7 2256/4885SCN9A 503/4885CYP1A2 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.